logo
Scientists say they have solved the mystery of what killed more than 5 billion sea stars

Scientists say they have solved the mystery of what killed more than 5 billion sea stars

Yahoo20 hours ago
Sea Star Disease
WASHINGTON (AP) — Scientists say they have at last solved the mystery of what killed more than 5 billion sea stars off the Pacific coast of North America in a decade-long epidemic.
Sea stars – often known as starfish – typically have five arms and some species sport up to 24 arms. They range in color from solid orange to tapestries of orange, purple, brown and green.
Starting in 2013, a mysterious sea star wasting disease sparked a mass die-off from Mexico to Alaska. The epidemic has devastated more than 20 species and continues today. Worst hit was a species called the sunflower sea star, which lost around 90% of its population in the outbreak's first five years.
'It's really quite gruesome,' said marine disease ecologist Alyssa Gehman at the Hakai Institute in British Columbia, Canada, who helped pinpoint the cause.
Healthy sea stars have 'puffy arms sticking straight out,' she said. But the wasting disease causes them to grow lesions and 'then their arms actually fall off.'
The culprit? Bacteria that has also infected shellfish, according to a study published Monday in the journal Nature Ecology and Evolution.
The findings 'solve a long-standing question about a very serious disease in the ocean," said Rebecca Vega Thurber, a marine microbiologist at University of California, Santa Barbara, who was not involved in the study.
It took more than a decade for researchers to identify the cause of the disease, with many false leads and twists and turns along the way.
Early research hinted the cause might be a virus, but it turned out the densovirus that scientists initially focused on was actually a normal resident inside healthy sea stars and not associated with disease, said Melanie Prentice of the Hakai Institute, co-author of the new study.
Other efforts missed the real killer because researchers studied tissue samples of dead sea stars that no longer contained the bodily fluid that surrounds the organs.
But the latest study includes detailed analysis of this fluid, called coelomic fluid, where the bacteria Vibrio pectenicida were found.
'It's incredibly difficult to trace the source of so many environmental diseases, especially underwater,' said microbiologist Blake Ushijima of the University of North Carolina, Wilmington, who was not involved in the research. He said the detective work by this team was 'really smart and significant.'
Now that scientists know the cause, they have a better shot at intervening to help sea stars.
Prentice said that scientists could potentially now test which of the remaining sea stars are still healthy — and consider whether to relocate them, or breed them in captivity to later transplant them to areas that have lost almost all their sunflower sea stars.
Scientists may also test if some populations have natural immunity, and if treatments like probiotics may help boost immunity to the disease.
Such recovery work is not only important for sea stars, but for entire Pacific ecosystems because healthy starfish gobble up excess sea urchins, researchers say.
Sunflower sea stars 'look sort of innocent when you see them, but they eat almost everything that lives on the bottom of the ocean,' said Gehman. 'They're voracious eaters.'
With many fewer sea stars, the sea urchins that they usually munch on exploded in population – and in turn gobbled up around 95% of the kelp forest s in Northern California within a decade. These kelp forests provide food and habitat for a wide variety of animals including fish, sea otters and seals.
Researchers hope the new findings will allow them to restore sea star populations -- and regrow the kelp forests that Thurber compares to 'the rainforests of the ocean.'
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

BD Businesses Become First in MedTech to Achieve HIRC's Diamond Badge Across All Supply Chain Resiliency Categories
BD Businesses Become First in MedTech to Achieve HIRC's Diamond Badge Across All Supply Chain Resiliency Categories

Yahoo

time29 minutes ago

  • Yahoo

BD Businesses Become First in MedTech to Achieve HIRC's Diamond Badge Across All Supply Chain Resiliency Categories

FRANKLIN LAKES, N.J., Aug. 5, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its Urology and Critical Care (UCC) and Surgery business units are the first in the medical technology industry to achieve a diamond-level rating for all seven supply chain resilience domains of the Healthcare Industry Resilience Collaborative's (HIRC) Resiliency Badging program. "Achieving HIRC's Diamond Status Resiliency Badge recognizes BD's commitment to building a resilient end-to-end supply chain across multiple product categories and our relentless pursuit of process excellence and continuous improvement," said Tony Ezell, executive vice president and president of the Americas region for BD. "Hundreds of millions of patients depend on BD, and this recognition is a testament to the work our team does every day to ensure products arrive on time and in the right quantities." HIRC is a non-profit health care supply chain trade association founded in 2019 by a group of health care systems and trading partners focused on increasing transparency and resiliency. The Resiliency Badge Program includes a rigorous audit to assess supply chain resiliency, ensuring alignment with HIRC's standards for supply continuity, risk mitigation and operational efficiency. After completing a comprehensive audit, HIRC recognized BD for differentiated resiliency in all domain areas for its Surgery and UCC businesses, including demand planning, supplier management, inventory management, logistics, supply chain visibility, risk management and continency planning, and operational health. BD was one of the first companies recognized by HIRC after receiving the Transparency Partner Badge in 2023. This diamond-level distinction builds on that recognition and demonstrates BD's ongoing investment in its supply chain and manufacturing operations, including increasing safety stock and capacity to allow greater flexibility for the most critical products and improving order management interfaces so customers have real-time insights into supply and deliveries. About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit or connect with us on LinkedIn at X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. Contacts: Media: Investors: Fallon McLoughlin Adam Reiffe BD Corporate Communications BD Investor Relations 201.258.0361 201.847.6927 View original content to download multimedia: SOURCE BD (Becton, Dickinson and Company) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Enanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. "HCW@Home" Series
Enanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. "HCW@Home" Series

Yahoo

time29 minutes ago

  • Yahoo

Enanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. "HCW@Home" Series

WATERTOWN, Mass., August 05, 2025--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in a virtual fireside chat on Tuesday, August 12, 2025 at 1:00 p.m. ET as part of the H.C. Wainwright & Co. "HCW@Home" series. A live webcast of the event will be accessible by visiting the "Events and Presentations" section on the "Investors" page of Enanta's website at or by registering here. A replay of the webcast will be available following the presentation and will be archived for at least 30 days. About Enanta Pharmaceuticals, is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta's clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing Hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta's royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta's operations. Please visit for more information. View source version on Contacts Media and Investors Contact: Jennifer Viera617-744-3848jviera@

Here's Why UnitedHealth Group (UNH) Sold Off Sharply in Q2
Here's Why UnitedHealth Group (UNH) Sold Off Sharply in Q2

Yahoo

time29 minutes ago

  • Yahoo

Here's Why UnitedHealth Group (UNH) Sold Off Sharply in Q2

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its 'RiverPark Large Growth Fund' Q2 2025 investor letter. A copy of the letter can be downloaded here. U.S. equity markets surged in the second quarter, with the S&P 500 Total Return Index rising 10.94% and the Russell 1000 Growth Index returning 17.84%. The fund also surged in the quarter and returned 15.01%. Continued enthusiasm for artificial intelligence, better-than-expected earnings in several large-cap growth sectors, and improving macroeconomic conditions lifted the markets in the quarter. Growth-focused stocks took the lead once more, with the strongest performance coming from sectors like technology, communication services, and certain areas of consumer discretionary. In addition, please check the fund's top five holdings to know its best picks in 2025. In its second-quarter 2025 investor letter, RiverPark Large Growth Fund highlighted stocks such as UnitedHealth Group Incorporated (NYSE:UNH). UnitedHealth Group Incorporated (NYSE:UNH) is a diversified healthcare company that operates through UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx segments. The one-month return of UnitedHealth Group Incorporated (NYSE:UNH) was -21.68%, and its shares lost 57.60% of their value over the last 52 weeks. On August 4, 2025, UnitedHealth Group Incorporated (NYSE:UNH) stock closed at $240.98 per share, with a market capitalization of $218.603 billion. RiverPark Large Growth Fund stated the following regarding UnitedHealth Group Incorporated (NYSE:UNH) in its second quarter 2025 investor letter: "UnitedHealth Group Incorporated (NYSE:UNH): UNH was the portfolio's weakest performer in Q2. The company's Q1 results, reported in April, showed 5% revenue growth but declining earnings as medical cost ratios rose to 84.8%. Higher-than-expected utilization in outpatient procedures, particularly among Medicare Advantage and Medicaid patients, pressured margins. The company subsequently lowered full-year guidance during its June investor update. A senior healthcare professional giving advice to a patient in a clinic. UnitedHealth Group Incorporated (NYSE:UNH) is in 18th position on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 139 hedge fund portfolios held UnitedHealth Group Incorporated (NYSE:UNH) at the end of the first quarter, which was 150 in the previous quarter. While we acknowledge the potential of UnitedHealth Group Incorporated (NYSE:UNH) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered UnitedHealth Group Incorporated (NYSE:UNH) and shared the list of best dividend stocks to buy and hold forever. Baron Health Care Fund chose to exit UnitedHealth Group Incorporated (NYSE:UNH) during Q2 2025. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store